Abstract

The Molecular Biology Shared Resource seeks to provide the highest quality oligonucleotide synthesis and DNA sequence analysis services in a timely, convenient and cost-effective manner to support the research programs of the Cancer Center. In addition, we provide expert design, data analysis and application troubleshooting assistance. The facility currently operates one Perkin Elmer Biosystems 377 DNA sequencer and two Perkin Elmer 394 oligo synthesizers. During the last three years there has been a substantial increase in use of this shared resource reflecting the quality, convenience and value of the shared provided. Our most striking accomplishment has been the growth in utilization of our DNA sequencing services, increasing from analysis of less than 2400 templates in 1996-1997 to more than 7000 templates in the last year. Utilization of our oligonucleotide synthesis services has also steady grown with an increase from preparation of approximately 2000 oligonucleotides in 1996-1997 to synthesis of almost 2400 oligonucleotides in the last year. We have cared out a niche for this service in the university by combining highest coupling efficiency available with expert assistance with design, convenient ordering methods, and fast turnaround times. Oligonucleotides are ready for the Cancer Center member by the next morning.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA069533-04
Application #
6401790
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1997-08-01
Project End
2005-05-31
Budget Start
Budget End
Support Year
4
Fiscal Year
2000
Total Cost
Indirect Cost

  Institution

Name
Oregon Health and Science University
Department
Type
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239

  Publications

Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Chen, Emerson Y; Blanke, Charles D; Haller, Daniel G et al. (2018) A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol 41:1193-1198
Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028

Showing the most recent 10 out of 277 publications